NMN-H is a next-generation longevity formulation centred around UTHPeak® NMN-H (Reduced β-Nicotinamide Mononucleotide), an advanced and highly stable form of NMN developed to support cellular NAD+ levels, energy metabolism, and healthy ageing.
UTHPeak® NMN-H represents a significant evolution beyond conventional NMN. As the reduced form of NMN, NMN-H demonstrates enhanced stability and resistance to degradation, allowing for improved preservation of the molecule prior to absorption. This stability is critical, as standard NMN is known to degrade under certain conditions, potentially limiting its effectiveness.
Once absorbed, NMN-H contributes to the replenishment of nicotinamide adenine dinucleotide (NAD+), a vital coenzyme involved in mitochondrial energy production, DNA repair, and cellular signalling. NAD+ levels naturally decline with age, and this reduction is associated with decreased cellular function, reduced metabolic efficiency, and impaired stress response.
By supporting NAD+ availability, NMN-H plays a role in:
Cellular energy production via mitochondrial function
Activation of longevity-associated pathways, including sirtuins
DNA repair and cellular maintenance processes
Healthy metabolic function
Age-related decline in cellular performance
UTHPeak® is manufactured using advanced purification and stabilisation processes to ensure high-quality, pharmaceutical-grade NMN-H with consistent potency and integrity. The inclusion of inulin (Orafti® Synergy1) further supports formulation stability and may contribute to gastrointestinal tolerance and prebiotic support.
NMN-H is positioned within the NeoGenesis Longevity Range as a targeted solution for individuals seeking advanced support for cellular vitality, metabolic efficiency, and healthy ageing processes.